Global Biomarkers Market, By Type (Safety, Efficacy, Validation), Application (Diagnostics Development, Drug Discovery and Development, Personalized Medicine, Disease-Risk Assessment, Others), Product Type (Consumables, Services, Software), Technology (Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers), Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Immunological Disorders, Others) – Industry Trends and Forecast to 2030.
Biomarkers Market Analysis and Size
Biomarkers are utilized to see how well the body responds to a treatment for a condition or disease. These biomarkers are known as signature molecules and molecular markers. The increase in the prevalence of cancer is raising the demand for biomarkers.
Data Bridge Market Research analyses that the global biomarkers market which was USD 43.13 million in 2022, would rocket up to USD 153.34 million by 2030, and is expected to undergo a CAGR of 14.90% during the forecast period. “Safety” dominates the type segment of the biomarkers market owing to the growing demand for personalized medicine. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
2023 to 2030
2021 (Customizable to 2015-2020)
Revenue in USD Million, Volumes in Units, and Pricing in USD
By Type (Safety, Efficacy, and Validation), Application (Diagnostics Development, Drug Discovery and Development, Personalized Medicine, Disease-Risk Assessment, and Others), Product Type (Consumables, Services, and Software), Technology (Safety Biomarkers, Efficacy Biomarkers, and Validation Biomarkers), Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Immunological Disorders, and Others)
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America
Market Players Covered
Enzo Biochem Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Merck KGaA (Germany), PerkinElmer Inc. (U.S.), QIAGEN (Germany), Agilent Technologies, Inc. (U.S.), Bruker (U.S.), Epigenomics AG (Germany), MESO SCALE DIAGNOSTICS, LLC (U.S.), EKF Diagnostics Holdings plc (U.K.), General Electric Company (U.S.), Nexus- Dx (U.S.), LifeSign LLC (U.S.), F.Hoffman- La Roche Ltd (Switzerland), Thermo Fischer Scientific Inc. (U.S.), Eurofins Scientific (Luxembourg), Abbott (U.S.), Charles River Laboratories International Inc. (U.S.), Sino Biological, Inc. (China), and CENTOGENE N.V. (Germany)
Biomarkers are referred to as minimally or non-invasive tools. These are integrated with key imaging and data management technologies. These tools are widely utilized in imaging technology to provide clear imaging of oncology tumors and other problems. Biomarkers reduce the chance of radiation exposure during imaging through MRI and CT scans.
Biomarkers Market Dynamics
- Rising Burden of Cancer
Biomarkers are essential in combating the rising burden of cancer by enabling early detection, precise diagnosis, treatment selection, and disease monitoring. Biomarkers can be used to screen for and detect cancer early, allowing for prompt treatment while the condition is more curable. Blood tests and liquid biopsies are two examples of biomarker-based screening techniques that can identify the presence of particular biomarkers linked to particular malignancies. In addition, biomarkers can forecast how likely it is that a patient will respond to a given therapy or treatment. Healthcare professionals can identify patients who are more likely to benefit from a particular therapy approach, such as targeted medicines or immunotherapies, by analyzing biomarkers.
- Growing Investment in Biomarker Research
Investment in biomarker research has increased as a result of scientific developments, improved knowledge of biomarker utility, the potential for therapeutic effect, and supporting regulatory frameworks. Because they make it possible for early detection, precise diagnosis, wise treatment decisions, and ongoing illness monitoring, biomarkers have the potential to completely change the way healthcare is provided. Pharmaceutical businesses, biotechnology companies, research institutes, and governmental organizations have all made large investments in the hope of improving patient outcomes and lowering healthcare costs. This in turn helps the lucrative growth of the market.
- Rising Advancements in Genomics and Proteomics
Researchers now understand more about the underlying molecular mechanisms of disease due to advances in genomics and proteomics, which have also made it easier to identify biomarkers with clinical significance. The search for biomarkers has been transformed by genomics and proteomics technology. It is now possible to quickly and affordably sequence entire genomes or particular sections of interest using high-throughput sequencing techniques like next-generation sequencing (NGS). As a result, new possible biomarkers have been discovered. This has made it easier to identify genetic variants, mutations, and modifications linked to diseases.
- Increasing Demand for Personalized Medicine
In the growing field of "personalized medicine," biomarkers are becoming an increasingly significant factor. They are useful for choosing the right dose and prognosis prediction. In addition, they might be useful for identifying therapeutic and unfavorable reactions as well as for patient classification based on efficacy or safety forecasts. "Providing the right treatment to the right patient, at the right dose, at the right time," biomarkers are crucial instruments for the selection of suitable patients for treatment with certain pharmaceuticals. This in turn the demand for personalized medicine is expected to act as a driver for the market growth.
- Increasing Usage of Biomarkers in Clinical Trials
The use of biomarkers in clinical trials is expanding quickly and changing the clinical research environment. Biomarkers are useful tools in the development of new medicines because they offer insightful information about disease biology, therapy response, and patient stratification. Biomarkers are being used more frequently by pharmaceutical companies to speed up medication development, lower expenses, and boost the likelihood that clinical trials will be successful. The need for biomarkers that can help with medication development, clinical trial planning, and discovery is anticipated to increase. This act as an opportunity for market growth.
- Rising Demand for Point-of-Care Testing (POCT)
Since biomarkers are essential for providing quick and convenient diagnostic testing at the point of care, POCT and biomarkers are closely related. In point-of-care diagnostics, biomarkers are used to identify and quantify particular biological markers linked to diseases or other health issues. These biomarkers can be found utilizing portable devices or rapid diagnostic kits, giving medical professionals and patients immediate and practical results. This act as an opportunity for market growth.
- Complexity and Variability of Biomarkers
The development, validation, and therapeutic application of biomarkers are significantly hampered by their complexity and variability. The molecular makeup of biomarkers can vary widely and include proteins, nucleic acids (DNA, RNA), metabolites, and other substances. Each form of biomarker has its own unique set of complications, such as the necessity for specialized detection techniques or difficulties with sample collection and processing. The complexity of biomarker research and analysis increases with the need to deal with various types of biomarkers.
- Strict Regulatory Framework
Before being employed in clinical practice, biomarker-based diagnostics often need regulatory permission or clearance. The regulatory process is determined by the biomarker's intended use, which may be for diagnostic, prognostic, or predictive reasons. While other nations have their regulatory bodies, the Food and Drug Administration (FDA) of the United States is in charge of overseeing the approval procedure.
- Reimbursement Coverage for Biomarker Tests
Evidence supporting the clinical value and cost-effectiveness of biomarker tests is frequently required for reimbursement decisions. Data on test accuracy, clinical results, the effect on patient treatment, and potential cost savings are all part of this evidence. Particularly for novel biomarkers, generating the required proof can be time-consuming and expensive. Market availability and uptake of biomarker testing might be hampered by limited reimbursement coverage or delays in reimbursement decisions, particularly for new or innovative biomarkers.
- Cost Associated with Biomarker Discovery
The cost of finding a biomarker can vary widely depending on the size and breadth of the study, the intricacy of the disease or condition being investigated, and the accessibility of available infrastructure and resources. Access to the right research infrastructure, including lab space, specialized machinery, and data analysis tools, is necessary for the development of biomarkers. Such infrastructure can have large up-front and continuing expenditures to establish and maintain.
This biomarkers market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the biomarkers market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.
- In December 2021 CENTOGENE NV received the award based on its unique, AI-powered biomarker platform, CentoMetabolome. The internally implemented platform has the potential to revolutionize the identification of novel biomarkers by reducing the time required for research from months to just a few days. The CentoMetabolome platform's use cases include providing complete metabolome screening, locating potential biomarker candidates, and improving drug efficacy knowledge
- In May 2021, QIAGEN N.V. launch an FDA-approved tissue companion diagnostic to detect the KRAS G12C mutation in NSCLC tumors will aid in the company's expansion of its lung cancer precision medicine portfolio
Global Biomarkers Market Scope
The biomarkers market is segmented based on type, application, product type, technology, and indication. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Diagnostics Development
- Drug Discovery and Development
- Personalized Medicine
- Disease-Risk Assessment
- Safety Biomarkers
- Efficacy Biomarkers
- Validation Biomarkers
- Cardiovascular Disorders
- Neurological Disorders
- Immunological Disorders
Biomarkers Market Regional Analysis/Insights
The biomarkers market is analyzed and market size insights and trends are provided by country, type, application, product type, technology, and indication as referenced above.
The countries covered in the biomarkers market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.
North America dominates the biomarkers market because of the high use of biomarkers in personalized medicine within the region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increasing burden of cancer worldwide, growing research activities in the region, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The biomarkers market also provides you with detailed market analysis for every country's growth in healthcare expenditure for capital equipment, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios and their impact on the biomarkers market. The data is available for historic period 2021-2030.
Competitive Landscape and Biomarkers Market Share Analysis
The biomarkers market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the biomarkers market are:
- Enzo Biochem Inc. (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- Merck KGaA (Germany)
- PerkinElmer Inc. (U.S.)
- QIAGEN (Germany)
- Agilent Technologies, Inc. (U.S.)
- Bruker (U.S.)
- Epigenomics AG (Germany)
- MESO SCALE DIAGNOSTICS, LLC (U.S.)
- EKF Diagnostics Holdings plc (U.K.)
- General Electric Company (U.S.)
- Nexus- Dx (U.S.)
- LifeSign LLC (U.S.)
- F.Hoffman- La Roche Ltd (Switzerland)
- Thermo Fischer Scientific Inc. (U.S.)
- Eurofins Scientific (Luxembourg)
- Abbott (U.S.)
- Charles River Laboratories International Inc.(U.S.)
- Sino Biological, Inc. (China)
- CENTOGENE N.V. (Germany)